CSPC PHARMA (01093): 8 latest clinical trial advances will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress
CSPC PHARMA (01093) announced that the Group will present 8 latest clinical trial advances at the European Society for Medical Oncology (ESMO) Annual Congress to be held in Madrid, Spain, from October 23 to October 27, 2026, of which 2 were selected as Late-breaking Abstracts (LBA). The 8 clinical advances selected will be presented in the form of 1 preferred oral presentation, 3 rapid oral presentations, 3 posters, and 1 e-poster, covering tumor types including breast cancer, lung cancer, gastric cancer, liver cancer, colon cancer, pancreatic cancer, and perivascular epithelioid cell tumor, fully demonstrating the Group's R&D strength and clinical research capabilities in the field of oncology treatment.
CSPC PHARMA (01093) announced that the Group will present 8 latest clinical trial advances at the European Society for Medical Oncology (ESMO) Annual Congress to be held in Madrid, Spain, from October 23 to October 27, 2026, of which 2 have been selected as Late-breaking Abstracts (LBA). The 8 clinical advances selected will be presented in the form of 1 preferred oral presentation, 3 rapid oral presentations, 3 posters, and 1 e-poster, covering tumor types including breast cancer, lung cancer, gastric cancer, liver cancer, colon cancer, pancreatic cancer, and perivascular epithelioid cell tumors, fully demonstrating the Group's R&D strength and clinical research capabilities in the field of oncology treatment.
Related Articles
AI compute demand outlook viewed favorably; BNP Paribas raises target prices for NVIDIA Corporation (NVDA.US) and Intel Corporation (INTC.US), but remains cautious on the latter.
SINOPHARM TECH (08156) restores public float
QINGLING MOTORS (01122): Enters into Xinjiang Lixin Energy commercial vehicle repurchase agreement, maximum repurchase price not exceeding RMB 12.636 million
AI compute demand outlook viewed favorably; BNP Paribas raises target prices for NVIDIA Corporation (NVDA.US) and Intel Corporation (INTC.US), but remains cautious on the latter.
SINOPHARM TECH (08156) restores public float
QINGLING MOTORS (01122): Enters into Xinjiang Lixin Energy commercial vehicle repurchase agreement, maximum repurchase price not exceeding RMB 12.636 million
